EE05127B1 - Osadest koosnev komplekt ja ravimpreparaat, mis sisaldavad P2T-retseptori antagonisti v?i selle farmatseutiliselt vastuv?etavat derivaati ja tromboosivastast ainet, ning nende kasutamine meditsiinis - Google Patents

Osadest koosnev komplekt ja ravimpreparaat, mis sisaldavad P2T-retseptori antagonisti v?i selle farmatseutiliselt vastuv?etavat derivaati ja tromboosivastast ainet, ning nende kasutamine meditsiinis

Info

Publication number
EE05127B1
EE05127B1 EEP200200271A EEP200200271A EE05127B1 EE 05127 B1 EE05127 B1 EE 05127B1 EE P200200271 A EEP200200271 A EE P200200271A EE P200200271 A EEP200200271 A EE P200200271A EE 05127 B1 EE05127 B1 EE 05127B1
Authority
EE
Estonia
Prior art keywords
kit
medicine
pharmaceutically acceptable
parts
receptor antagonist
Prior art date
Application number
EEP200200271A
Other languages
English (en)
Estonian (et)
Inventor
Dixon John
Humphries Robert
Jarvis Gavin
Kirk Ian
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of EE200200271A publication Critical patent/EE200200271A/xx
Publication of EE05127B1 publication Critical patent/EE05127B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EEP200200271A 1999-12-01 2000-11-29 Osadest koosnev komplekt ja ravimpreparaat, mis sisaldavad P2T-retseptori antagonisti v?i selle farmatseutiliselt vastuv?etavat derivaati ja tromboosivastast ainet, ning nende kasutamine meditsiinis EE05127B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9904377A SE9904377D0 (sv) 1999-12-01 1999-12-01 Pharmaceutical combinations
PCT/SE2000/002378 WO2001039781A1 (en) 1999-12-01 2000-11-29 Pharmaceutical combinations

Publications (2)

Publication Number Publication Date
EE200200271A EE200200271A (et) 2003-06-16
EE05127B1 true EE05127B1 (et) 2009-02-16

Family

ID=20417947

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200200271A EE05127B1 (et) 1999-12-01 2000-11-29 Osadest koosnev komplekt ja ravimpreparaat, mis sisaldavad P2T-retseptori antagonisti v?i selle farmatseutiliselt vastuv?etavat derivaati ja tromboosivastast ainet, ning nende kasutamine meditsiinis

Country Status (32)

Country Link
US (2) US20030032618A1 (cs)
EP (2) EP1719526A3 (cs)
JP (1) JP2003515565A (cs)
KR (1) KR100785953B1 (cs)
CN (1) CN1402639A (cs)
AR (1) AR033658A1 (cs)
AT (1) ATE332698T1 (cs)
AU (1) AU781691B2 (cs)
BR (1) BR0016043A (cs)
CA (1) CA2391161C (cs)
CO (1) CO5271717A1 (cs)
CY (1) CY1105211T1 (cs)
CZ (1) CZ300925B6 (cs)
DE (1) DE60029340T2 (cs)
DK (1) DK1237559T3 (cs)
EE (1) EE05127B1 (cs)
ES (1) ES2267591T3 (cs)
HU (1) HU230890B1 (cs)
IL (1) IL149495A0 (cs)
IS (1) IS2841B (cs)
MX (1) MXPA02004871A (cs)
MY (1) MY128896A (cs)
NO (1) NO331215B1 (cs)
NZ (2) NZ518904A (cs)
PT (1) PT1237559E (cs)
RU (1) RU2242232C2 (cs)
SE (1) SE9904377D0 (cs)
SI (1) SI1237559T1 (cs)
SK (1) SK288707B6 (cs)
TW (1) TWI251491B (cs)
WO (1) WO2001039781A1 (cs)
ZA (1) ZA200203707B (cs)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7132408B2 (en) 2000-08-21 2006-11-07 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
US7452870B2 (en) 2000-08-21 2008-11-18 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with P2Y12 receptor antagonist compound
US6897201B2 (en) 2000-08-21 2005-05-24 Inspire Pharmaceuticals, Inc. Compositions and methods for the treatment of glaucoma or ocular hypertension
US7115585B2 (en) 2000-08-21 2006-10-03 Inspire Pharmaceuticals, Inc. Compositions for treating epithelial and retinal tissue diseases
US7018985B1 (en) 2000-08-21 2006-03-28 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
DE10064797A1 (de) * 2000-12-22 2002-06-27 Knoll Ag Orale und parenterale pharmazeutische Formulierung, umfassend eine niedermolekulare Thrombininhibitor-Pro-Pharmakon
SE0101932D0 (sv) * 2001-05-31 2001-05-31 Astrazeneca Ab Pharmaceutical combinations
US7435724B2 (en) 2002-02-27 2008-10-14 Inspire Pharmaceutical, Inc. Degradation-resistant mononucleoside phosphate compounds
EP1604669A1 (en) * 2004-06-10 2005-12-14 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of ATP analogues for treatment of cardiovascular diseases
WO2007035028A1 (en) * 2005-09-21 2007-03-29 Chong Kun Dang Pharmaceutical Corp. Novel resinate complex of s-clopidogrel and production method thereof
US9427448B2 (en) 2009-11-11 2016-08-30 The Medicines Company Methods of treating, reducing the incidence of, and/or preventing ischemic events
US20120141468A1 (en) 2008-05-13 2012-06-07 Lisa Ruderman Chen Maintenance of platelet inhibition during antiplatelet therapy
US20130303477A1 (en) 2008-05-13 2013-11-14 The Medicines Company Maintenance of Platelet Inhibition During Antiplatelet Therapy
WO2009140092A1 (en) 2008-05-13 2009-11-19 The Medicines Company Maintenance of platelet inhibition during antiplatelet therapy
US8759316B2 (en) 2008-05-13 2014-06-24 The Medicines Company Maintenance of platelet inhibition during antiplatelet therapy
EP2498731B1 (en) 2009-11-11 2020-01-22 Chiesi Farmaceutici S.p.A. Methods of treating or preventing stent thrombosis
US10376532B2 (en) 2009-11-11 2019-08-13 Chiesi Farmaceutici, S.P.A. Methods of treating, reducing the incidence of, and/or preventing ischemic events
AU2012214396B2 (en) 2011-02-09 2017-04-27 Chiesi Farmaceutici S.P.A. Methods for treating pulmonary hypertension
EP3978002A1 (en) 2013-03-09 2022-04-06 Chiesi Farmaceutici S.p.A. Methods of treating, reducing the incidence of, and/or preventing ischemic events
ES3067885T3 (en) 2017-06-23 2026-05-26 Chiesi Farm Spa Cangrelor for the treatment and/or prevention of shunt or stent thrombosis

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8826448D0 (en) * 1988-11-11 1988-12-14 Thrombosis Res Inst Improvements in/relating to organic compounds
EP0579643A1 (en) * 1991-04-06 1994-01-26 FISONS plc Atp analogues
DE69406649T2 (de) * 1993-02-10 1998-03-05 Astra Pharmaceuticals Ltd., Kings Langley, Hertfordshire N-alkyl-2-substituierte atp-analoge
IL110040A (en) * 1993-06-29 2000-07-16 Nissan Chemical Ind Ltd Pyridazinone derivatives their preparation and pharmaceutical compositions comprising them
MA23420A1 (fr) * 1994-01-07 1995-10-01 Smithkline Beecham Corp Antagonistes bicycliques de fibrinogene.
SE9404196D0 (sv) * 1994-12-02 1994-12-02 Astra Ab New antithrombotic formulation
DE19515500A1 (de) * 1995-04-27 1996-10-31 Thomae Gmbh Dr K Substituierte Phenylamidine, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
WO1997003084A1 (en) * 1995-07-11 1997-01-30 Astra Pharmaceuticals Ltd. New inhibitors of platelet aggregation
WO1999065500A1 (en) * 1998-06-17 1999-12-23 Bristol-Myers Squibb Company Preventing cerebral infarction through administration of adp-receptor antiplatelet and antihypertensive drugs in combination
SE9802973D0 (sv) * 1998-09-03 1998-09-03 Astra Ab Immediate release tablet
TWI229674B (en) * 1998-12-04 2005-03-21 Astra Pharma Prod Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
US6462021B1 (en) * 2000-11-06 2002-10-08 Astrazeneca Ab Use of low molecular weight thrombin inhibitor
US6696468B2 (en) * 2002-05-16 2004-02-24 Dainippon Pharmaceutical Co., Ltd. (s)-4-amino-5-chloro-2-methoxy-n-[1-[1-(2-tetrahydrofuryl-carbonyl)-4-piperidinylmethyl]-4-piperidinyl]benzamide, process for the preparation thereof, pharmaceutical composition containing the same, and intermediate therefor
US20040067995A1 (en) * 2002-10-02 2004-04-08 Wong Pancras C. Novel combination of a factor Xa inhibitor and clopidogrel
EP1652532A1 (en) * 2003-07-16 2006-05-03 Kyowa Hakko Kogyo Co., Ltd. Medicinal composition

Also Published As

Publication number Publication date
ATE332698T1 (de) 2006-08-15
DK1237559T3 (da) 2006-10-30
AU1910901A (en) 2001-06-12
TWI251491B (en) 2006-03-21
SK7502002A3 (en) 2003-02-04
MXPA02004871A (es) 2002-08-30
CZ300925B6 (cs) 2009-09-09
PT1237559E (pt) 2006-10-31
NZ518904A (en) 2004-02-27
EP1237559B1 (en) 2006-07-12
CN1402639A (zh) 2003-03-12
EP1719526A2 (en) 2006-11-08
CO5271717A1 (es) 2003-04-30
NZ530058A (en) 2005-04-29
DE60029340T2 (de) 2007-07-19
AR033658A1 (es) 2004-01-07
HUP0203585A3 (en) 2005-01-28
EE200200271A (et) 2003-06-16
HUP0203585A2 (hu) 2003-03-28
SE9904377D0 (sv) 1999-12-01
SI1237559T1 (sl) 2007-02-28
IS6398A (is) 2002-05-27
WO2001039781A1 (en) 2001-06-07
IS2841B (is) 2013-08-15
SK288707B6 (sk) 2019-10-02
AU781691B2 (en) 2005-06-09
US20060270607A1 (en) 2006-11-30
CZ20021887A3 (cs) 2002-11-13
DE60029340D1 (de) 2006-08-24
IL149495A0 (en) 2004-03-28
EP1719526A3 (en) 2007-04-25
HK1047893A1 (en) 2003-03-14
ZA200203707B (en) 2003-10-29
JP2003515565A (ja) 2003-05-07
NO20022606D0 (no) 2002-05-31
NO331215B1 (no) 2011-11-07
KR100785953B1 (ko) 2007-12-14
MY128896A (en) 2007-02-28
EP1237559A1 (en) 2002-09-11
BR0016043A (pt) 2002-07-23
HU230890B1 (hu) 2018-12-28
CY1105211T1 (el) 2010-03-03
RU2242232C2 (ru) 2004-12-20
CA2391161C (en) 2010-10-05
KR20020069201A (ko) 2002-08-29
CA2391161A1 (en) 2001-06-07
ES2267591T3 (es) 2007-03-16
PL355841A1 (en) 2004-05-17
RU2002117296A (ru) 2004-01-20
NO20022606L (no) 2002-07-11
US20030032618A1 (en) 2003-02-13

Similar Documents

Publication Publication Date Title
EE05171B1 (et) Peroraalne ravimvorm, mis sisaldab opioidagonisti vabanevas vormis ja eraldatud opioidantagonisti, meetod selle valmistamiseks ning selle kasutamine meditsiinis
EE04965B1 (et) Imidasoimidasoolid ja triasoolid kui p?letikuvastased hendid, nende kasutamine ravimite valmistamiseks ning farmatseutiline kompositsioon
EA200401009A1 (ru) Предварительно желатинированный крахмал в композиции с контролируемым высвобождением
HUP0401047A3 (en) Triazolo[4,5-d]pyrimidine derivatives, their use as purinergic receptor antagonist and pharmaceutical compositions containing same
EE9800181A (et) Gonadotropiini riliisinghormooni antagonist, selle kasutamine, farmatseutiline kompositsioon ja selle valmistamismeetod
HUP9603298A3 (en) Heterocyclic compounds having tachykinin receptor antagonist activity, their preparation, and their use for the preparation of pharmaceutical compositions
AR017296A1 (es) Uso de un antagonista del receptor de 5-hidroxitriptamina y compuestos antagonistas
EE9700328A (et) Tahke oraalne preparaat, mis sisaldab toimeainena olansapiini, selle valmistamismeetod ja kasutamine
HUP0203638A3 (en) Betha2-adrenergic receptor agonists and pharmaceutical compositions containing them and their use
EE200200046A (et) 8-fenüül-6,9-dihüdro-[1,2,4]triasolo[3,4-i]puriin-5-ooni derivaat, selle valmistamine ja raviotstarbeline kasutamine ning seda sisaldav farmatseutiline kompositsioon
ID22565A (id) Penggunaan nanodispersi dalam formulasi akhir obat
EE200200202A (et) Uudsed tritsüklilised ühendid, nende saamine ja kasutamine ravimi valmistamiseks, mis on ette nähtud HIV-nakkuse raviks, ning neid sisaldav farmatseutiline kompositsioon
SE0002754D0 (sv) New pharmaceutical combination formulation and method of treatment with the combination
RU2002105377A (ru) Ксенон-антагонист nmda
IL149495A0 (en) Pharmaceutical formulations comprising p2t receptor antagonist and anti-thrombotic agent and use thereof in therapy
EE04997B1 (et) Loteprednooli ja antihistamiinseid aineid sisaldav farmatseutiline kompositsioon, neid aineid sisaldav ravim, meetod selle ravimi valmistamiseks ja nende ainete kombinatsiooni kasutamine
BRPI0008228B8 (pt) composição farmacêutica contendo n-benzoil estaurosporina e agentes solubilizantes
AU9018898A (en) Phosphazole-containing nucleoside analogs, related compounds, pharmaceutical compositions thereof, and their use in in vitro medicinal treatments
PT1230230E (pt) Derivados de indeno-di-hidrotiazole sua preparacao e sua utilizacao como medicamentos anorexigenico
PT1210119E (pt) Composicoes farmaceuticas para administracao oral e topica
BRPI0414558A (pt) composição farmacêutica compreendendo um antagonista do receptor p2x7 e uma droga antiinflamatória não esteróide
EE200100388A (et) Püridasino [4,5-b] indool-1-atseetamiidi derivaatide kasutamine ravimite valmistamiseks perifeersete bensodiasepiiniretseptorite düsfunktsioneerimisega seotud haiguste raviks
SE9902935D0 (sv) Pharmaceutical compositions
HUP0200707A3 (en) N-(2-phenyl-4-amino-butyl)-1-naphthamides as neurokinin-1 receptor antagonists pharmaceutical compositions containing them and their use
NO20002526D0 (no) Mellomprodukt med høyt legemiddelinnhold og orale doseringspreparater med modifisert frigivelse samt fremgangsmÕter for fremstilling derav

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20101231